Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 226 results for hypertension in adults

  1. Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)

    Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease in adults.

    Technology appraisal guidance
    Published
    28 October 2015
    View recommendations

    Sections for TA358

  2. Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)

    Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    5 June 2019
    View recommendations

    Sections for TA584

  3. Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)

    Evidence-based recommendations on cabozantinib (Cabometyx) for advanced hepatocellular carcinoma in adults who have had sorafenib.

    Technology appraisal guidance
    Published
    14 December 2022
    View recommendations

    Sections for TA849

  4. Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)

    Evidence-based recommendations on edoxaban (Lixiana) for treating deep vein thrombosis and pulmonary embolism in adults and preventing them happening again.

    Technology appraisal guidance
    Published
    26 August 2015
    View recommendations

    Sections for TA354

  5. Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)

    Evidence-based recommendations on ibrutinib (Imbruvica) with venetoclax (Venclyxto) for untreated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    31 May 2023
    View recommendations

    Sections for TA891

  6. Endoscopic sleeve gastroplasty for obesity (HTG711)

    Evidence-based recommendations on endoscopic sleeve gastroplasty for obesity. This involves using an endoscopic device to fold the stomach in on itself and stitch it together to reduce its volume.

    HealthTech guidance
    Published
    22 February 2024
    View recommendations

    Sections for HTG711

  7. Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema following retinal vein occlusion in adults.

    Technology appraisal guidance
    Published
    27 July 2011
    View recommendations

    Sections for TA229

  8. Hyperhidrosis: oxybutynin (ES10)

    Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

    Evidence summary
    Published
    21 March 2017

  9. Ruxolitinib for treating polycythaemia vera (TA921)

    Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.

    Technology appraisal guidance
    Published
    18 October 2023
    View recommendations

    Sections for TA921

  10. Forward view - our priority topics

    Our forward view highlights the topics we will prioritise in the coming year.

  11. The AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation (MIB18)

    NICE has developed a Medtech Innovation Briefing (MIB) on the AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation

    Medtech innovation briefing
    Published
    12 February 2015

  12. Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)

    Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    19 October 2022
    View recommendations

    Sections for TA830

  13. The SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional changes in people with or at risk of developing glaucoma (MIB14)

    NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional

    Medtech innovation briefing
    Published
    19 November 2014

  14. Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic hormone-relapsed prostate cancer in adults who have had treatment with docetaxel-containing chemotherapy.

    Technology appraisal guidance
    Published
    23 July 2014
    View recommendations

    Sections for TA316

  15. Peripheral arterial disease (QS52)

    This quality standard covers diagnosing and managing lower limb peripheral arterial disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    21 January 2014
    View quality statements

    Sections for QS52